Market Overview

UPDATE: Paradigm Capital Lowers PT to $67 on Valeant Pharmaceuticals on Raising Interest Cost

Related VRX
Are There Any Winners Left In The Biotech Space?
Zoetis Inc. Spikes Briefly On Remarks From Sanofi CEO
Energy Sector Seen as Biggest Risk to Deal Flow in 2015 (Fox Business)

Paradigm Capital reiterated its Buy rating on Valeant Pharmaceuticals (NYSE: VRX) but lowered its price target from $70 to $67 ahead of the quarterly earnings release.

Paradigm Capital commented, "We continue to hold a positive view toward Valeant's unique approach to running a specialty pharmaceutical company, which we believe sets it apart from its peers. That said, the debt raised recently to pay for the Medicis acquisition leads to a material increase in interest payments, which dilutes the company's earnings power. We are lowering our price target to $67.00 (from $70.00) to account for these interest payments."

Valeant Pharmaceuticals closed at $54.62 on Tuesday.

Latest Ratings for VRX

DateFirmActionFromTo
Oct 2014Cantor FitzgeraldMaintainsBuy
Oct 2014JefferiesMaintainsBuy
Aug 2014Cantor FitzgeraldMaintainsBuy

View More Analyst Ratings for VRX
View the Latest Analyst Ratings

Posted-In: Paradigm CapitalAnalyst Color Price Target Intraday Update Analyst Ratings

 

Related Articles (VRX)

Around the Web, We're Loving...

Get Benzinga's Newsletters